NCT03876106View on ClinicalTrials.gov

A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 21, 2019

Primary Completion Date

July 9, 2020

Study Completion Date

November 18, 2020

Conditions
EGFR Inhibitor Induced Acneiform Lesions
Interventions
DRUG

LUT014

Topical

Trial Locations (6)

10022

Memorial Sloan Kettering Cancer Center, New York

63110

Washington University School of Medicine-Dermatology, St Louis

77030

MD Anderson Cancer Center, Houston

90404

UCLA Health Santa Monica - Cancer Care, Los Angeles

4941492

Rabin Medical Center, Petah Tikva

5266202

Sheba Medical Center, Ramat Gan

Sponsors

Lead Sponsor

Lutris Pharma Ltd.
All Listed Sponsors
lead

Lutris Pharma Ltd.

INDUSTRY

NCT03876106 - A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions | Biotech Hunter | Biotech Hunter